{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Study+sample+collection&page=20", "query": { "intervention": "Study sample collection", "page": 20 }, "page_size": 10 }, "pagination": { "page": 20, "page_size": 10, "total_count": 2548, "total_pages": 255, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Study+sample+collection&page=21&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Study+sample+collection&page=19&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-20T20:52:08.014Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06050252", "title": "Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Resectable Intrahepatic Cholangiocarcinoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Resection", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2024-07-10", "completion_date": "2027-02-12", "has_results": false, "last_update_posted_date": "2026-09-04", "last_synced_at": "2026-10-20T20:52:08.014Z", "location_count": 57, "location_summary": "Irvine, California • Los Angeles, California • Orange, California + 47 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Derby", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT06050252" }, { "nct_id": "NCT04517838", "title": "Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Adenocarcinoma", "HER2-Positive Breast Carcinoma", "Anatomic Stage I Breast Cancer AJCC v8", "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 230, "start_date": "2020-07-31", "completion_date": "2028-07-27", "has_results": false, "last_update_posted_date": "2026-06-16", "last_synced_at": "2026-10-20T20:52:08.014Z", "location_count": 1, "location_summary": "Jacksonville, Florida", "locations": [ { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04517838" }, { "nct_id": "NCT01209585", "title": "A Study to Evaluate BioMarkers in Blood Samples in Subjects With Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Arthritis" ], "interventions": [ { "name": "Blood samples", "type": "OTHER" }, { "name": "Synovial fluid aspiration", "type": "OTHER" }, { "name": "Synovial tissue sample", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 23, "start_date": "2011-03", "completion_date": "2013-03", "has_results": false, "last_update_posted_date": "2013-07-25", "last_synced_at": "2026-10-20T20:52:08.014Z", "location_count": 3, "location_summary": "Frederick, Maryland • Wyomissing, Pennsylvania • Jackson, Tennessee", "locations": [ { "city": "Frederick", "state": "Maryland" }, { "city": "Wyomissing", "state": "Pennsylvania" }, { "city": "Jackson", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01209585" }, { "nct_id": "NCT02160015", "title": "Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Chronic Lymphocytic Leukemia", "Recurrent Small Lymphocytic Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Electrocardiogram", "type": "PROCEDURE" }, { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2014-05-20", "completion_date": "2027-08-19", "has_results": false, "last_update_posted_date": "2026-08-21", "last_synced_at": "2026-10-20T20:52:08.014Z", "location_count": 2, "location_summary": "Washington D.C., District of Columbia • Hackensack, New Jersey", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT02160015" }, { "nct_id": "NCT02282917", "title": "Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Vestibular Schwannoma", "Meningioma", "Acoustic Neuroma", "Neurofibromatosis Type 2" ], "interventions": [ { "name": "AR-42", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts Eye and Ear Infirmary", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2015-12", "completion_date": "2021-01-04", "has_results": true, "last_update_posted_date": "2025-12-05", "last_synced_at": "2026-10-20T20:52:08.014Z", "location_count": 4, "location_summary": "Stanford, California • Baltimore, Maryland • Boston, Massachusetts + 1 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02282917" }, { "nct_id": "NCT06757647", "title": "Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Acalabrutinib", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging of the Heart", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Seema Bhat", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2025-05-27", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2025-12-16", "last_synced_at": "2026-10-20T20:52:08.014Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06757647" }, { "nct_id": "NCT02843347", "title": "STRIDE Biorepository", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Anemia, Sickle Cell" ], "interventions": [ { "name": "Blood draw", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "15 Years to 40 Years" }, "enrollment_count": 200, "start_date": "2017-03-13", "completion_date": "2023-07", "has_results": false, "last_update_posted_date": "2021-02-08", "last_synced_at": "2026-10-20T20:52:08.014Z", "location_count": 40, "location_summary": "Oakland, California • Washington D.C., District of Columbia • Gainesville, Florida + 28 more", "locations": [ { "city": "Oakland", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02843347" }, { "nct_id": "NCT05478538", "title": "Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform (ELEPHAS-01)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "NSCLC (Non-small Cell Lung Cancer)", "Metastatic NSCLC - Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Core Needle, Forceps, or Punch Biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Elephas", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2023-01-31", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-06-29", "last_synced_at": "2026-10-20T20:52:08.014Z", "location_count": 7, "location_summary": "Los Angeles, California • Frederick, Maryland • Shirley, New York + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Frederick", "state": "Maryland" }, { "city": "Shirley", "state": "New York" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Canton", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05478538" }, { "nct_id": "NCT05064553", "title": "ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hepatocellular Carcinoma", "Hepatocellular Cancer", "Hepatitis B", "Cirrhosis", "Liver Cancer" ], "interventions": [ { "name": "Study CT/MRI Imaging", "type": "DEVICE" }, { "name": "Standard of Care CT/MRI Imaging", "type": "DEVICE" }, { "name": "Oncoguard™ Liver Test", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DEVICE", "DIAGNOSTIC_TEST" ], "sponsor": "Exact Sciences Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2990, "start_date": "2021-07-26", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2025-10-15", "last_synced_at": "2026-10-20T20:52:08.014Z", "location_count": 76, "location_summary": "Chandler, Arizona • Sun City, Arizona • Bakersfield, California + 62 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Escondido", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05064553" }, { "nct_id": "NCT04394858", "title": "Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Adrenal Gland Pheochromocytoma", "Advanced Paraganglioma", "Metastatic Adrenal Gland Pheochromocytoma", "Metastatic Paraganglioma", "Stage III Adrenal Gland Pheochromocytoma and Sympathetic Paraganglioma AJCC v8", "Stage IV Adrenal Gland Pheochromocytoma and Sympathetic Paraganglioma AJCC v8", "Unresectable Adrenal Gland Pheochromocytoma", "Unresectable Paraganglioma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography with Contrast", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 46, "start_date": "2021-03-17", "completion_date": "2028-03-01", "has_results": false, "last_update_posted_date": "2026-09-10", "last_synced_at": "2026-10-20T20:52:08.014Z", "location_count": 163, "location_summary": "Anchorage, Alaska • Burbank, California • Fort Lauderdale, Florida + 120 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04394858" } ] }